Crystagen 20mg
Immune System Peptide Bioregulator for Immune Cell Research
Crystagen is a Khavinson tetrapeptide bioregulator targeting immune cells of the lymphatic system, supporting immune cell gene expression normalization and immune function in aging models.
Immune System Peptide Bioregulator for Immune Cell Research
Lymphatic/immune tissue-specific peptide bioregulator supporting normal lymphocyte gene expression and immune competence through epigenetic modulation.
As one of the most studied compounds in the recovery & healing research space, Crystagen has attracted sustained scientific interest across Immune system research, Lymphocyte biology studies. Peer-reviewed evidence indicates that immune tissue Khavinson bioregulator, which has positioned Crystagen as a reference standard for researchers exploring immune system research outcomes. The compound's selectivity and documented tolerability in preclinical models have contributed to a rapidly growing body of literature over the past decade.
Crystagen Documented Benefits: 1 Documented Mechanisms
Immune Cell Support
Normalizes lymphocyte gene expression and supports immune system function.
How Crystagen Works: Molecular Mechanism & Pathway
Short peptide with immune cell tissue specificity, modulating epigenetic gene expression in lymphocytes for immune homeostasis.
The 1 primary research pathways identified for Crystagen — Immune Cell Support — collectively point to a compound with pleiotropic activity across interconnected biological systems. Studies have further shown that lymphocyte gene expression normalization, reinforcing the mechanistic picture established in earlier cell-line work. Unlike single-pathway agents, Crystagen's broad receptor engagement profile continues to generate hypotheses for novel applications beyond its originally characterized use cases.
Research Protocols & Compound Combinations
Crystagen is routinely studied alongside TA-1 and Thymulin in recovery & healing-focused compound panels. Researchers investigating immune system research have found that pairing compounds with complementary receptor profiles can produce additive results while keeping individual doses within well-characterized ranges. Preliminary evidence that 20mg research standard has informed several of these multi-compound protocol designs.
Purity, Testing & Research Grade Standards
All Crystagen research material offered through this catalog is manufactured under controlled conditions and independently verified by a third-party laboratory prior to release. Each lot undergoes High-Performance Liquid Chromatography (HPLC) analysis to confirm ≥98% purity, with identity confirmed via mass spectrometry. The accompanying Certificate of Analysis (CoA) documents the exact purity, molecular weight confirmation, and lot-specific testing date — data that should accompany any reproducible research protocol. Lyophilized powder formulation ensures maximum stability during shipping and storage at −20°C long-term or 4°C for short-term use.
◈ Key Highlights
- Immune tissue Khavinson bioregulator
- Lymphocyte gene expression normalization
- 20mg research standard
Ideal For
- Immune system research
- Lymphocyte biology studies
Intended for laboratory use only. Not for human or animal consumption. Not FDA approved. Handle in appropriate lab settings only.
What the Research Shows
The following data points are derived from peer-reviewed preclinical and clinical studies on Crystagen. All studies cited in compound profiles are indexed in PubMed or published in peer-reviewed journals.
Immune tissue Khavinson bioregulator
Lymphocyte gene expression normalization
20mg research standard
Third-Party Verified Every Batch
Each vial of Crystagen is independently tested by a third-party laboratory before fulfillment. You receive the actual CoA (Certificate of Analysis) documentation with your order.
